Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2607883 | 0.85 | LMNA (0.54) | LMNAGAAMAPTALDH1A1POLB | |
| SCHEMBL9883923 | 0.84 | TSHR (0.59) | LMNAMAPTPOLBTSHRHSD17B10 | |
| SCHEMBL12417193 | 0.82 | LMNA (0.50) | LMNAGAAMAPTALDH1A1POLB | |
| SCHEMBL28919595 | 0.82 | LMNA (0.60) | LMNAGAAMAPTALDH1A1POLB | |
| SCHEMBL18862772 | 0.79 | LMNA (0.47) | LMNAGAAMAPTPOLBTDP1 | |
| SCHEMBL25492272 | 0.79 | — | — | |
| SCHEMBL15355916 | 0.79 | — | — | |
| SCHEMBL7753090 | 0.77 | LMNA (0.57) | LMNAALDH1A1POLBRECQLTSHR | |
| SCHEMBL5909180 | 0.77 | LMNA (0.57) | LMNAMAPTPOLBRECQLTSHR | |
| SCHEMBL28682753 | 0.77 | TSHR (0.50) | LMNAGAAMAPTPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161553-A1 | Angiogenesis inhibitors, compositions containing same and use thereof for treating diseases related to angiogenetic deregulation | SYNT:EM (FR) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161553-A1 | Angiogenesis inhibitors, compositions containing same and use thereof for treating diseases related to angiogenetic deregulation | EDF1, RUNX1, FLT1 | LMNA 2213/4885GAA 1770/4885MAPT 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.